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The design and characterization of a new family of multifunctional scaffolds based on 
bioactive glass (BG) of 45S5 composition for bone tissue engineering and drug delivery 
applications are presented. These BG-based scaffolds are developed via a replication 
method of polyurethane packaging foam. In order to increase the therapeutic func-
tionality, the scaffolds were coated with mesoporous silica particles (MCM-41), which 
act as an in  situ drug delivery system. These sub-micron spheres are characterized 
by large surface area and pore volume with a narrow pore diameter distribution. The 
solution used for the synthesis of the silica mesoporous particles was designed to obtain 
a high-ordered mesoporous structure and spherical shape – both are key factors for 
achieving the desired controlled drug release. The MCM-41 particles were synthesized 
directly inside the BG-based scaffolds, and the drug-release capability of this combined 
system was evaluated. Moreover, the effect of MCM-41 particle coating on the bioactivity 
of the BG-based scaffolds was assessed. The results indicate that it is possible to obtain 
a multifunctional scaffold system characterized by high and interconnected porosity, high 
bioactivity, and sustained drug delivery capability.
Keywords: ordered mesoporosity, silica, McM-41, bioactive glass, scaffolds, drug release, ibuprofen
inTrODUcTiOn
One of the most promising fields of tissue engineering is the development of porous 3D engineered 
scaffolds to enhance bone regeneration and neovascularization (Porter et al., 2009). The main chal-
lenge is the design of materials able to match at the same time the biological and the mechanical 
properties of the natural bone tissue (Mastrogiacomo et al., 2006; Stevens, 2008; Philippart et al., 
2015). However, the design of the scaffolds is not the only challenge, in fact the first problem after 
implantation is the exposure to inflammatory and infection risks with further complications, e.g., 
septicemia and potential implant failure (Misch and Wang, 2008). To avoid these consequences, 
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a large amount of antibiotics and anti-inflammatory drugs are 
administered to the patient, which can increase the healing time, 
the stay at the hospital, and costs (Neut et al., 2003). Nowadays, 
the most popular ways for drug intake are oral administration 
and injection. However, these methods may be affected by a 
lack of efficiency especially since the release of the drug is not 
targeted to the area that needs to be treated (Vallet-Regí et al., 
2012a). For all these reasons, the development of local drug-
release systems, which enable controlled release kinetics, has 
increased considerably during the past few years (Vallet-Regí, 
2006a; Slowing et  al., 2007; Cotí et  al., 2009; Vitale-Brovarone 
et  al., 2009; Wu et  al., 2013). In this context, the combination 
of bioactive scaffolds with local drug delivery carriers is gaining 
increasing research efforts in the bone tissue engineering field 
(Philippart et al., 2015). Several matrices have been tested so far, 
such as organic polymers, organic–inorganic hybrid materials, 
bioactive glasses (BG), and ceramics (Wu and Chang, 2014). One 
approach gaining increasing interest involves obtaining drug 
carriers that are structured at the nanoscale. Since 1992, when 
silica-based MCM-41 was developed (Mobil Composition of 
Matter No. 41) (Beck et  al., 1992), highly ordered mesoporous 
materials have attracted the attention of many scientists and in 
2001 they were proposed as drug delivery system (Vallet-Regí 
et al., 2001). The most interesting features of these materials are 
the regular pore system, high specific surface area and high pore 
volume (Vallet-Regí et al., 2001, 2012a,b; Vallet-Regí, 2006b; Zhao 
et al., 2013). These silica-based mesoporous materials are able to 
incorporate relatively high content of drugs into the mesopores. 
Moreover, their silanol groups can be functionalized (Figure 1) 
and the pore diameter can be modulated, allowing a better 
control of the drug-release kinetic (Grün et al., 1997; Vallet-Regí 
et  al., 2001, 2012b; Vallet-Regí, 2006b; Wu and Chang, 2014). 
Two mechanisms have been proposed to describe mesoporous 
silica material formation. The first model describes the addition 
FigUre 1 | Main features of the mesoporous silica materials (figure 
modified from Vallet-regí, 2006b).
of silicate to micelles formed using n-decyltrimethylammonium 
bromide. In this way, the silica precursor polymerizes around the 
already formed micelles (Zhao et al., 2013). The second proposed 
mechanism is that the addition of the silica precursor to an aque-
ous n-decyltrimethylammonium bromide solution induces the 
ordering of silica-encased surfactant micelles simultaneously. In 
this case, the micelle formation requires the silica precursor to be 
present (Vallet-Regí et al., 2012a; Zhao et al., 2013).
MCM-41 has become the most popular member of the 
mesoporous silicate materials family, and it has been considered 
also as drug carrier.(Vallet-Regí et al., 2012b) Nowadays, it is pos-
sible to find in literature different approaches for the synthesis of 
spherical MCM-41 (Grün et al., 1999; Cai et al., 2001; Zeleňák 
et al., 2008; Liu et al., 2009). Grün et al. (1997, 1999) proposed 
a novel pathway for the production of spherical MCM-41 apply-
ing a modification of the Stöber reaction (Stober and Fink, 
1968) for the synthesis of spherical non-porous silica particles. 
The approach involves introducing a low-boiling alcohol, such 
as ethanol or isopropanol, as co-solvent for the silica source in 
order to get a more homogeneous solution (Grün et al., 1999). 
Starting from the work of Grün et  al. (1999), it is possible to 
obtain well-shaped spherical particles; however, the mesoporos-
ity is not homogeneously present. On the other hand, following 
a standard procedure reported by Zeleňák et  al. (2008), it is 
possible to obtain well-ordered mesoporous structures; however, 
the particles are not spherical and the size distribution is usually 
broad. Combining these two synthesis pathways, a new solution 
for the synthesis of spherical mesoporous silica particles has 
been proposed in this study. Thus, the aim of the present work 
is the synthesis of spherical silica mesoporous particles (MCM-
41) inside porous BG-based scaffolds [45S5 BG composition 
(Hench, 2015)] to combine in the same system the drug uptake 
and release capabilities of this mesoporous material with the bio-
activity properties of the BG. The concept of incorporating a silica 
drug carrier into bioactive silicate scaffolds has been previously 
explored (Mortera et al., 2008); however, the main advantage of 
the approach introduced in this paper is the possibility to obtain 
a highly homogeneous coating of the BG scaffold struts with 
highly ordered mesoporous silica particles without affecting the 
BG bioactivity. Moreover, the total amount of produced particles 
obtained per single batch increases by ~60% combining the two 
standard procedures reported in literature (Grün et  al., 1999; 




The procedure adopted to prepare MCM-41 was a combination 
of the standard pathway for the production of mesoporous silica 
particles and a modification of the Stöber reaction (Stober and 
Fink, 1968) for the preparation of non-porous silica spheres pro-
posed by Grün et al. (1999). In this way, the reaction took place 
in a more homogeneous environment, resulting in the formation 
of sub-micron sized spherical MCM-41 particles and the total 
amount of the cationic surfactant, which is extremely toxic, can be 
TaBle 1 | composition of four different synthesis solutions used for the 











MCM-41_A (Zelenˇák  
et al., 2008)
29 – 18.5 0.2 1
MCM-41_B 11 18 18.5 0.2 1
MCM-41_C 4 25 18.5 0.2 1
MCM-41_D (Grün  
et al., 1999)
11 19 3.3 0.62 1.25
FigUre 2 | scheme of the coating of Bg-based scaffolds with 
mesoporous silica particles and heat-treatment schedule used.
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reduced (Grün et al., 1999). A low-boiling alcohol such as ethanol 
was added as co-solvent for the tetra-n-alkoxysilane to make it 
soluble. The reactants were ammonia (catalyst of the reaction), 
n-hexadecyltrimethylammonium bromide (CTAB, surfactant), 
pure ethanol (co-solvent of silica source), and tetraethyl ortho-
silicate (TEOS), all purchased from Sigma-Aldrich (Germany). 
Pure ethanol and ammonia (28–30 wt.%) solution were mixed 
with deionized water. The cationic surfactant was added to the 
solution under continuous stirring for 20  min. Once the solu-
tion was clear, TEOS was added (0.25 mL min−1). All synthesis 
steps were carried out at room temperature (RT), which is the 
optimal temperature condition for the reaction with cationic 
surfactant in basic conditions as reported by Zhao et al. (2013). 
After 2  h of stirring, the resulting dispersion was centrifuged 
and washed once with deionized water and twice with ethanol in 
order to remove completely every trace of ammonia, collected in 
a ceramic crucible, dried, and calcined in air. The solutions used 
are reported in Table 1. For samples MCM-41_A (Zeleňák et al., 
2008), MCM-41_B, and MCM-41_C, the thermal treatment was 
60°C (2°C  min−1) for 12  h and 550°C (2°C  min−1) for 6  h; for 
sample MCM-41_D (Grün et al., 1999), the thermal treatment 
was 90°C (2°C min−1) for 12 h and 550°C (1°C min−1) for 5 h.
scaffolds Preparation
The template used to prepare 3D porous scaffolds was polyure-
thane (PU) packaging foams (45 ppi) (Eurofoam Deutschland 
GmbH Schaumstoffe). BG powder (particle size 5 μm of 45S5 
composition) was used. 45S5 BG-based scaffolds were produced 
by the replica technique, according to the method described by 
Chen et al. (2006). Briefly, the slurry for the scaffolds fabrication 
was prepared by dissolving polyvinyl alcohol (PVA) in deion-
ized water at 80°C for 1 h, the concentration being 0.01 mol L−1. 
Then, 45S5 BG powder was added to 25 mL PVA–water solution 
to obtain a concentration of 40 wt.%. Each procedure was car-
ried out under vigorous stirring using a magnetic stirrer for 1 h. 
The sacrificial PU templates, cut to cylinders (7 mm in height 
and 5 mm in diameter), were immersed in the slurry for 10 min. 
The foams were retrieved and the extra slurry was completely 
squeezed out manually. The samples were then dried at RT for 
at least 12 h. The dip coating in the slurry was repeated three 
times to increase the coating thickness and consequently the 
mechanical properties. After the second and third coating, 
the extra slurry was completely removed using compressed air 
as explained elsewhere (Boccardi et  al., 2015). Post-foaming 
heat treatment for the burning-out of the sacrificial template 
and sintering of the BG structure was programed. The burn-
ing and sintering conditions were: 400°C for 1  h and 1050°C 
for 1 h, respectively. The heating and cooling rates were 2 and 
5°C min−1, respectively.
composite system Preparation
MCM-41_A, MCM-41_B, and MCM-41_D samples were 
used for the preparation of BG_MCM-41 composite scaffolds. 
MCM-41_C solution was not used because it did not show 
any ordered mesoporosity. The coating procedure used here 
was similar to the one reported by Mortera et al. (2008). The 
procedure consisted of four steps, i.e., hydrolysis of TEOS in 
MCM-41-synthesis solution, dipping of scaffolds for particles 
impregnation, drying of the scaffolds, and calcination (heat 
treatment) for the removal of the surfactant. After TEOS 
addition, the solution was stirred for 10  min to promote 
the hydrolysis of the silica precursor. Scaffolds were then 
immersed in the silica synthesis batch for 10 min and mean-
while the solution was kept under vigorous stirring in order 
to enhance the coating of the inner core of the BG scaffolds. 
The resulting BG-based scaffolds coated with the MCM-41 
particles were heat-treated at 60°C (2°C  min−1) for 12  h for 
drying and at 550°C (2°C min−1) for 6 h in air as reported in 
Figure 2.
Drug-release Test
To load silica particles with a drug, Ibuprofen (>98%, purchased 
from Sigma-Aldrich) as model drug was dissolved in hexane 
(33  mg  mL−1) and MCM-41 particles were added to the drug 
solution (33 mg mL−1) at RT following the procedure presented 
in literature (Vallet-Regí et al., 2001). The samples with the drug 
solution were then placed in a vacuum hood at RT at 300 mbar 
for 10 min in order to enhance the drug infiltration inside the 
mesoporosity. After 12 h, this procedure was repeated, the drug 
solution was removed and the particles were dried in a vacuum 
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hood at RT. All the particle synthesis solutions were tested for 
their drug-releasing capability.
The scaffolds coated with MCM-41_B were in contact with the 
drug solution for 3 days (10 mg mL−1) before the starting of the 
drug-release test, in order to get a better infiltration of the drug. 
Only the scaffolds coated with MCM-41_B particles were consid-
ered for the test, because the resulting particles were still spherical 
and with ordered mesoporosity and the results were compared 
with those obtained on scaffolds not coated with MCM-41.
The drug-release kinetics from all samples, particles (10 mg 
each sample), and scaffolds was assessed by soaking the samples 
in 4 mL of PBS, kept at 37°C until the complete release of ibu-
profen. At every time point, 1 mL of solution was uptake for the 
drug-release analysis and substituted with 1 mL of fresh PBS. A 
UV-vis spectrophotometer was used to evaluate the amount of 
released drug. The calibration curve was calculated using a solu-
tion of ibuprofen in PBS with different known concentrations, 
on the basis of the absorption at 273 nm, typical of this molecule 
(Vallet-Regí et al., 2001).
Bioactivity and stability of the composite 
system
Simulated body fluid (SBF) was prepared by dissolving reagent-
grade 8.035  g  L−1 NaCl, 0.355  g  L−1 NaHCO3, 0.225  g  L1 KCl, 
0.231 g L−1 K2HPO4 (3H2O), 0.311 g L−1 MgCl2 (6H2O), 0.292 g L−1 
CaCl2, and 0.072 g L−1 Na2SO4 in deionized water and buffered at 
pH 7.4 at 36.5°C with 6.118 g L−1 tris(hydroxymethyl) aminometh-
ane [(CH2OH)3CNH2] and 1M HCl, as previously reported by 
Kokubo and Takadama (2007). Cylindrical BG foams coated 
and not coated with mesoporous silica particles were immersed 
in SBF at a 1.5 g L−1 ratio (Cerruti et al., 2005). The stability of 
the MCM-41 coating was evaluated in Tris-buffered solution 
[tris(hydroxymethyl) aminomethane]. Only the scaffolds coated 
with MCM-41_B were tested, because the silica particles showed 
suitable features in terms of homogeneous coating, shape, and 
ordered mesoporosity. In both cases, the solution was kept in a 
polystyrene container at 37°C in a shaking incubator (90 rpm) 
up to 1 week. The solution was renewed every 2 days in order to 
better mimic the in vivo behavior, as carried out also in previous 
studies (Chen et al., 2006). At the end of the incubator period, 
the foams were washed with deionized water, dried, and stored 
for further characterizations.
characterization Techniques
The shape and the surface structure of the resulting MCM-41 
particles and BG_MCM-41 were evaluated by means of scan-
ning electron microscope (SEM) (Auriga 0750 from ZEISS). 
The porous structure of the particles was assessed with high-
resolution transmission electron microscopy (HRTEM) (Phillips 
CM30) operating at an acceleration voltage of 300  kV. For the 
TEM observation, the samples were dispersed with ethanol on 
a lacey carbon film. The pore diameter analyses were conducted 
on HRTEM images with ImageJ analysis software. Small angle 
X-ray diffraction (SAXRD), carried out using Philips Xpert 
Diffractometer, was used to analyze the porous structure and 
the pore diameter of the silica particles. Diffraction data were 
recorded between 1 and 10° 2θ at an interval of 0.02° 2θ. Nitrogen 
adsorption desorption analysis was conducted at 77  K in a 
Quantachrome Autosorb Instrument to assess the specific surface 
area and the pore size of the particles. Prior to the measurements, 
the samples were outgassed for 12 h at 300°C under vacuum. The 
specific surface area and pore size of MCM-41 microspheres were 
evaluated, respectively, with BET method and BJH method.
resUlTs
McM-41 Particles
The morphology and the microstructure of the obtained MCM-
41 particles were assessed by HRTEM micrographs. HRTEM 
images of sample MCM-41_A and MCM-41_B showed the 
existence of highly ordered hexagonal array and streaks structural 
features (Figures 3a–d). The hexagonal array and the streaks are 
the view of the crystals whose axes are, respectively, parallel and 
perpendicular to the line of vision. Sample MCM-41_C, which 
was prepared with a high concentration of ethanol in the synthe-
sis solution, was porous however the porosity was not ordered 
(Figures 3e,f). Moreover MCM-41_D particles were porous but 
the porosity was not completely ordered, in contrast with the 
results reported in literature (Grün et al., 1999) (Figures 3g,h). 
From the analysis of the HRTEM images with ImageJ analysis 
software, the dimension of the pores was evaluated, which was 
found to be around 3 nm for all samples (Figure 4). The analysis 
has been done applying the Fast Fourier Transform (FFT) and 
the inverse FFT (Figure 4A) to the image, and the plug in plot 
(Figure 4B) has been used to evaluate the distance between the 
pore channels.
The pore size dimensions were confirmed also by SAXRD 
analysis. The spectra of sample MCM-41_A exhibited three 
sharp peaks, called Bragg peaks, indicating the long-range 
order present in the material, which is typical of MCM-41 
materials (Vallet-Regí et al., 2001) (Figure 5A) in agreement 
with literature (Grün et  al., 1999). These peaks arise from 
the quasi-regular arrangement of the mesopores in the bulk 
material (Grün et al., 1999; Vallet-Regí et al., 2001). The Bragg 
peaks can be indexed assuming a hexagonal symmetry. 2 theta 
values of sample MCM-41_A namely 2.75, 4.65, and 5.10 can 
be indexed as (100), (110), and (200) reflections, respectively. 
These values were close to those reported by Grün et al. (1999). 
The repeating distance, a0, between two pore centers may 
be calculated by a0 =  (2/√3)d100. The pore diameter can be 
evaluated from a0 subtracting 1.0 nm, which is approximately 
the value of the pore wall thickness (Grün et  al., 1999). For 
MCM-41_B particles, it was possible to identify unequivo-
cally only the main peak (100) (Figure  5B), meanwhile the 
110 and 200 peaks were less pronounced but still visible. The 
SAXRD results combined with HRTEM results confirm thus 
the mesoporous ordered structures of MCM-41_A and MCM-
41_B particles.
For samples MCM-41_C and MCM-41_D, only the main 
peak (100) was identified, in agreement with the HRTEM analy-
sis (Figures 5C,D). The first peak is in fact an indicator of the 
presence of mesoporosity in the sample. Also in this case, it was 
FigUre 3 | hrTeM images of sample McM-41_a (a,b) and sample McM-41_B (c,d), which are characterized by ordered mesoporosity, sample 
McM-41_c (e,f) and McM-41_D (g,h), which are characterized by a disordered porosity.
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FigUre 4 | high-resolution image of the ordered mesoporous 
structure of McM-41_B after analysis with FFT and inverse FFT (a); 
plot of the distance between the pore channels obtained with imageJ 
plug in plot applied along the yellow line (B).
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possible to evaluate the pore diameter with the Bragg’s law and 
the resulting values were in agreement with the ImageJ analysis.
The nitrogen isotherms of sample MCM-41_B are shown in 
Figure 6. The isotherms can be classified as type IV isotherms 
according to the IUPAC nomenclature for MCM-41 (Vallet-Regí 
et al., 2012a; Zhao et al., 2013), which is typical of mesoporous 
material with pore diameter in the range of 2–10  nm. MCM-
41_B particles were characterized by a specific surface area of 
951 m2 g−1 and a pore volume of 0.24 cm3 g−1. From Figure 7, 
it was possible to observe how the different amounts of solvent 
influenced the final shape and mesostructure of the resulting 
MCM-41 particles. The particles produced with only deionized 
water (Figures  7a,b) as solvent were characterized by hex-
agonal and not spherical geometry (MCM-41_A). Progressively 
increasing the amount of ethanol as co-solvent, it was possible to 
produce spherical particles, which exhibited a fairly homogene-
ous distribution of particle size but reduced mesoporosity order 
(Figures 7e,f).
composite scaffold system
From SEM analysis, it was possible to observe that the surface 
of scaffolds was completely coated after immersion in the 
MCM-41 synthesis batch maintaining an open porosity. In the 
case of the synthesis solution of MCM-41_A (Zeleňák et  al., 
2008) (Figures  8a,b), the one without ethanol as co-solvent, 
the shape of the resulting MCM-41 particles was seen to be 
completely changed. The presence of the scaffold affected the 
formation of the particles, probably due to a reduction in the 
homogeneity of the solution. Moreover, with this solution, 
FigUre 5 | saXrD of sample McM-41_a (a), McM-41_B (B), McM-41_c (c), and McM-41_D (D). Sample MCM-41_A is characterized by the three peaks, 
labeled as 100, 110, and 200.
FigUre 6 | nitrogen adsorption desorption isotherms on McM-41_B.
FigUre 7 | hrTeM images of the porous structure of samples prepared with different ratios water/ethanol: (a,b) sample McM-41_a, no ethanol, and 
20 min of stirring following the standard synthesis procedure (Zelenˇák et al., 2008), (c,d) sample McM-41_B, 60% ethanol and 20 min stirring, (e,f) 
sample McM-41_c, 90% ethanol, and 2 h stirring.
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it was not possible to obtain a homogenous coverage of the 
BG scaffold surface. With the synthesis solution of samples 
MCM-41_B (Figures 8c,d) and MCM-41_D (Grün et al., 1999) 
(Figures 8e,f), the resulting particles on the surface of the BG 
scaffolds were still perfectly spherical and they covered com-
pletely the surface of the scaffold struts. By means of HRTEM 
analysis, it was also possible to confirm that the MCM-41_B 
particles still exhibited ordered mesoporosity, as shown in 
Figure 9.
Drug-release capability of McM-41 
Particles
The drug-release capability of the different mesoporous silica 
particles was evaluated and the released profiles are reported 
in Figure  10. Both samples MCM-41_A (Figure  10A) and 
MCM-41_D (Figure 10D) were characterized by a burst release 
and it was confirmed that after 1 h of test, the 80% of the loaded 
drug was released. The rest 20% of the drug was released within 
the next 7  days. The particles prepared with solutions MCM-
41_B and MCM-41_C showed the best drug-release profile 
(Figures 10B,C), in terms of lack of uncontrolled burst release. 
Especially MCM-41_B, which was characterized by high-ordered 
mesoporosity, did not show any burst release during the first hours 
of the test. Eighty percent of the loaded drug was in fact released 
only after 30 h and the rest of the ibuprofen was released within 
the seven following days. It should be pointed out that ibuprofen 
solubility in water at 25°C is 21 mg L−1 (Vallet-Regí et al., 2001). 
During the present release test, the highest concentrations of 
ibuprofen were lower than its solubility, also after the first hours 
of release. At every time point, 1 mL of fresh PBS was added to 
every sample to keep constant the PBS volume and for this reason 
the solution was highly diluted.
Drug-release capability of composite 
scaffold system
The amounts of released ibuprofen from the BG and BG_MCM-
41_B scaffolds are shown in Figure  11. The presence of the 
FigUre 8 | Bg-based scaffolds coated with McM-41_a (Zelenˇák et al., 2008) (a,b), McM-41_B (c,d), and McM-41_D (grün et al., 1999) (e,f).
FigUre 9 | hrTeM images of the McM-41_B particles coating of Bg-based scaffolds at different magnifications. TEM images of few MCM-41_B 
particles (a) and HRTEM image of a single particle were the ordered mesoporosity was observed (b).
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mesoporous silica particles increased the drug incorporation 
capability, but in both cases most of the drug was released during 
the first hours of the test. The uncoated BG scaffolds were able 
to uptake 31 mgIBU/gbioglass, the scaffolds coated with MCM-41_B 
could uptake 43 mgIBU/gbioglass.
immersion Test
BG-based scaffolds both uncoated and coated with MCM-
41_B particles were immersed in SBF at 37°C. After 1 week of 
immersion, it was possible to observe that the presence of the 
silica particles did not affect the bioactivity of the (crystallized) 
FigUre 10 | ibuprofen released profile from McM-41_a (a), McM-41_B (B), McM-41_c (c), and McM-41_D (D).
FigUre 11 | Drug-release profile from Bg scaffolds coated with 
mesoporous silica particles Bg_McM-41 (◾) and uncoated (•).
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BG struts. In fact on both samples, coated and not coated 
(Figure 12a), a hydroxycarbonate apatite (HCA) layer forma-
tion was seen to form (Figures 12c,d). Moreover, it was possible 
to confirm the stability of the MCM-41 coating: after 10 days 
in Tris buffered solution, it was possible to identify the layer of 
MCM-41 particles covered with the HCA deposit (Figure 12e). 
The HCA layer was well developed and a deposit was also seen to 
have formed on the surface of the silica particles (Figures 12f,g, 
black circle).
DiscUssiOn
One of the most investigated areas in the bone tissue engineer-
ing field is related to the development and characterization of 
mechanically robust and porous 3D scaffolds. The main chal-
lenge is the design of a material able to match at the same time 
the biological and mechanical properties of the natural bone and 
also release ions or drugs able to reduce the risk of inflamma-
tion and infections after the implantation. In a previous work of 
Mortera et al. (2008), the possibility to increase the functionality 
of BG-based porous scaffolds was considered using a coating 
with MCM-41 particles as drug delivery system. In this way, it 
was possible to combine in a single system the drug uptake and 
release capability of mesoporous materials with the bioactivity of 
BG. In the present work, a further development of this idea was 
presented, improving the homogeneity of the coating, assessing 
the bioactivity and stability of the composite system BG_MCM-
41. Four different solutions were evaluated for the preparation of 
mesoporous silica particles, and an optimal synthesis procedure 
was found (MCM-41_B). In fact, by combining two different 
synthesis pathways, both well known in literature (Grün et al., 
1999; Zeleňák et  al., 2008), it was possible to obtain particles 
characterized by spherical shape and high-ordered mesoporos-
ity as confirmed by HRTEM, SAXRD, and Nitrogen adsorption/
desorption analysis (specific surface area 951 m2 g−1, pore vol-
ume 0.24 cm3 g−1). Moreover, the efficiency of the synthesis was 
increased and the total amount of produced particles obtained 
per single batch increased up to 60% compared to the previous 
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synthesis procedure: every 500  mL of solution, 4  g of MCM-
41_B were produced. MCM-41_B showed the best drug-release 
profile not exhibiting any burst release during the first hours of 
the test. The 80% of the loaded drug was in fact released only 
after 30 h and the rest of the ibuprofen was released within the 
seven following days. The drug-release times obtained during 
this work are in agreement with previous studies on drug-release 
capability of mesoporous silica particles (Vallet-Regí et al., 2001). 
These novel synthesis solution was used for the coating of 3D BG 
scaffolds. Due to the high amount of particles produced during 
FigUre 12 | seM micrographs of Bg-based scaffolds uncoated (a) and coated with McM-41 (b–d) after 1 week in sBF; Bg_McM-41_B scaffolds 
after immersion in Tris buffered solution for 10 days (e–g).
the synthesis, a highly homogeneous coating of the scaffolds was 
obtained. After the coating procedure, the particles were still 
spherical in shape and also the ordered mesoporosity was not 
affected. This was an improvement compared to previous works, 
in which the coatings were not homogeneously distributed on 
the surface of the scaffolds and the particles were not charac-
terized by ordered mesoporosity (Mortera et  al., 2008). The 
system BG_MCM-41 was assessed to be bioactive. In fact after 
1 week of immersion in SBF on the surface of both coated and 
not coated scaffolds, a layer of HCA was observed. It has been 
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